SEC Company Response from Hepion Pharmaceuticals, Inc. (HEPA, CTRVP) (CIK 0001583771) (HEPA) — Jun 13, 2019
Hepion Pharmaceuticals, Inc. (HEPA, CTRVP) (CIK 0001583771)
Date: June 13, 2019 · CIK: 0001583771 · Accession: 0001104659-19-035346
AI Filing Summary & Sentiment
File numbers found in text: 333-231604
Letter
VIA EDGAR United States Securities Attention: Dorrie Yale Re: ContraVir Pharmaceuticals, Inc. Form S-1, as amended File No. 333-231604
Dear Ms. Yale:
ContraVir Pharmaceuticals, Inc. (the “Company”) hereby respectfully withdraws its request, dated June 12, 2019, that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Time, on Thursday, June 13, 2019. The Company intends to submit a revised acceleration request at a later date.
Please contact Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 if there are any questions with respect to this request.
Thank you,
CONTRAVIR PHARMACEUTICALS, INC.
By:
/s/ Robert Foster
Name:
Robert Foster
Title:
Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm ContraVir Pharmaceuticals, Inc. 399 Thornall Street Edison, NJ 08837 June 13, 2019 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Dorrie Yale Re: ContraVir Pharmaceuticals, Inc. Form S-1, as amended File No. 333-231604 Dear Ms. Yale: ContraVir Pharmaceuticals, Inc. (the “Company”) hereby respectfully withdraws its request, dated June 12, 2019, that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Time, on Thursday, June 13, 2019. The Company intends to submit a revised acceleration request at a later date. Please contact Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 if there are any questions with respect to this request. Thank you, CONTRAVIR PHARMACEUTICALS, INC. By: /s/ Robert Foster Name: Robert Foster Title: Chief Executive Officer